The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
new crispr treatment for sickle cell disease faces slow rollout challenges
Deshawn “DJ” Chow, a 19-year-old with sickle cell disease, received Casgevy, the first approved CRISPR-based treatment, after a year of waiting. Despite its promise, the rollout has been slow due to manufacturing complexities and insurance hurdles, with only a few patients treated since its December 2023 approval. Chow hopes the therapy will alleviate his pain and allow him to pursue activities like snowboarding, reflecting a cautious optimism for the future of sickle cell treatments.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.